About HiFiBiO
HiFiBiO is a company based in Paris (France) founded in 2013 by Liang Schweizer. HiFiBiO has raised $179.5 million across 3 funding rounds from investors including Kite Pharma, Legend Holdings and Mirae Asset Financial Services. HiFiBiO has completed 1 acquisition, including H-Immune. HiFiBiO offers products and services including DIS® Platform, EMUNKITUG, and HFB200604. HiFiBiO operates in a competitive market with competitors including GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
- Headquarter Paris, France
- Founders Liang Schweizer
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hifibio Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$179.5 M (USD)
in 3 rounds
-
Latest Funding Round
$75 M (USD), Series D
Jun 14, 2021
-
Investors
Kite Pharma
& 19 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HiFiBiO
HiFiBiO offers a comprehensive portfolio of products and services, including DIS® Platform, EMUNKITUG, and HFB200604.
Enables drug discovery through single cell tech and AI analytics
Antibody for potential oncology treatment in clinical trials
Antibody targeting inflammatory and immunology diseases
People of HiFiBiO
Unlock access to complete
Unlock access to complete
Funding Insights of HiFiBiO
HiFiBiO has successfully raised a total of $179.5M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $75 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HiFiBiO
HiFiBiO has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Kite Pharma, Legend Holdings and Mirae Asset Financial Services.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sequoia Capital is engaged in venture capital investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Tech & Offline focused early & growth stage VC firm investing in China
|
Locked | Locked | Locked |
Investor details for HiFiBiO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HiFiBiO
HiFiBiO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include H-Immune.
Investment portfolio details for HiFiBiO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developing MAb immunotherapies to treat cancer
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for HiFiBiO
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - HiFiBiO
Detailed financials for HiFiBiO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hifibio Comparisons
Peer comparison for HiFiBiO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HiFiBiO
HiFiBiO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of HiFiBiO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hifibio
Complete news archive for HiFiBiO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HiFiBiO
HiFiBiO was founded in 2013 and raised its 1st funding round 5 years after it was founded.
HiFiBiO is headquartered in Paris, France.
Liang Schweizer is the current CEO of HiFiBiO. They have also founded this company.
HiFiBiO is a funded company, having raised a total of $179.5M across 3 funding rounds to date.
HiFiBiO was established in 2013 in Paris, France, within the biotechnology sector. A platform is provided for antibody-based drug discovery, where entire B cell populations are screened through high-throughput, single-cell, functional methods. Next-generation sequencing and rapid DNA synthesis are integrated to target rare antibodies. Operations emphasize efficient identification and development of therapeutic candidates for pharmaceutical applications.
HiFiBiO's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
HiFiBiO offers DIS® Platform, EMUNKITUG, and HFB200604.
HiFiBiO has made 1 acquisition, including H-Immune.
HiFiBiO has 20 investors. Key investors include Kite Pharma, Legend Holdings, Mirae Asset Financial Services, Sequoia Capital, and Sherpa Healthcare Partners.